Compare · BIIB vs SLDB
BIIB vs SLDB
Side-by-side comparison of Biogen Inc. (BIIB) and Solid Biosciences Inc. (SLDB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and SLDB operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $28.68B, about 44.1x SLDB ($650.8M).
- Over the past year, BIIB is up 50.2% and SLDB is up 53.9% - SLDB leads by 3.7 points.
- BIIB has been more active in the news (11 items in the past 4 weeks vs 4 for SLDB).
- BIIB has more recent analyst coverage (25 ratings vs 15 for SLDB).
- Company
- Biogen Inc.
- Solid Biosciences Inc.
- Price
- $199.87+2.86%
- $7.09+7.34%
- Market cap
- $28.68B
- $650.8M
- 1M return
- +0.23%
- -7.98%
- 1Y return
- +50.21%
- +53.90%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 11
- 4
- Recent ratings
- 25
- 15
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Solid Biosciences Inc.
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Latest BIIB
- Biogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Amendment: Biogen Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Biogen upgraded by Needham with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Biogen Inc.
- Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
- EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus
- Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
- UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus
- Stoke Therapeutics to Present at Upcoming Investor Conferences in June
- Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson's Disease
Latest SLDB
- Solid Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 424B7 filed by Solid Biosciences Inc.
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Solid Biosciences to Participate at Upcoming Investor Conferences
- Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Solid Biosciences Inc.
- Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy
- Amendment: SEC Form SCHEDULE 13G/A filed by Solid Biosciences Inc.
- Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy